Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Wade Clapp

Showing results (71-80 of 117) with videos related to

Pageof 12
Sort By:
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 1, 2020
A molecular basis for neurofibroma-associated skeletal manifestations in NF1Yun Ma, Andrea M Gross, Eva Dombi, et al.
Cancer Research|October 11, 2017
A Collaborative Model for Accelerating the Discovery and Translation of Cancer TherapiesOphélia Maertens, Mila E McCurrach, Benjamin S Braun, et al.
Research Square|June 30, 2025
An induced pluripotent stem cell model of Schwann cell differentiation reveals NF2- related gene regulatory networksOlivia Lazaro, Sihong Li, William Carter, et al.
The Journal of Clinical Investigation|December 18, 2003
Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cellsFeng-Chun Yang, David A Ingram, Shi Chen, et al.
Stem Cells (Dayton, Ohio)|January 15, 2015
Pak2 regulates hematopoietic progenitor cell proliferation, survival, and differentiationYi Zeng, Hal E Broxmeyer, Karl Staser, et al.
The Journal of Experimental Medicine|April 20, 2005
Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonistHal E Broxmeyer, Christie M Orschell, D Wade Clapp, et al.
Plos One|October 8, 2011
The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1Xiaohua Wu, Shi Chen, Yongzheng He, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2019
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomaScott R Plotkin, Dan G Duda, Alona Muzikansky, et al.
Pediatric Blood & Cancer|May 28, 2020
Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1Amy E Armstrong, Steven D Rhodes, Abbi Smith, et al.
Scientific Reports|December 24, 2025
Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal modelJennifer L Spiegel, Alessandro De Maio, Manita V Patel, et al.
Pageof 12

Showing results (71-80 of 117) with videos related to

Sort By:
Pageof 12
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 1, 2020
A molecular basis for neurofibroma-associated skeletal manifestations in NF1Yun Ma, Andrea M Gross, Eva Dombi, et al.
Cancer Research|October 11, 2017
A Collaborative Model for Accelerating the Discovery and Translation of Cancer TherapiesOphélia Maertens, Mila E McCurrach, Benjamin S Braun, et al.
Research Square|June 30, 2025
An induced pluripotent stem cell model of Schwann cell differentiation reveals NF2- related gene regulatory networksOlivia Lazaro, Sihong Li, William Carter, et al.
The Journal of Clinical Investigation|December 18, 2003
Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cellsFeng-Chun Yang, David A Ingram, Shi Chen, et al.
Stem Cells (Dayton, Ohio)|January 15, 2015
Pak2 regulates hematopoietic progenitor cell proliferation, survival, and differentiationYi Zeng, Hal E Broxmeyer, Karl Staser, et al.
The Journal of Experimental Medicine|April 20, 2005
Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonistHal E Broxmeyer, Christie M Orschell, D Wade Clapp, et al.
Plos One|October 8, 2011
The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1Xiaohua Wu, Shi Chen, Yongzheng He, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2019
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomaScott R Plotkin, Dan G Duda, Alona Muzikansky, et al.
Pediatric Blood & Cancer|May 28, 2020
Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1Amy E Armstrong, Steven D Rhodes, Abbi Smith, et al.
Scientific Reports|December 24, 2025
Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal modelJennifer L Spiegel, Alessandro De Maio, Manita V Patel, et al.
Pageof 12